File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

TitleDuration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
Authors
Issue Date2014
PublisherSpringer US. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0167-6806
Citation
Breast Cancer Research and Treatment, 2014, v. 146 n. 2, p. 421-7 How to Cite?
AbstractWomen with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80 %. Tamoxifen treatment of the first cancer has been associated with a reduction in the risk of a subsequent contralateral cancer. We studied 1,504 women with a known BRCA1 or BRCA2 mutation, 411 women with bilateral breast cancer (cases) and 1,093 women with unilateral breast cancer (controls) in a matched case–control study. Control women were of similar age and had a similar age of diagnosis of first breast cancer as the cases. For each woman who used tamoxifen, the starting and stopping dates were abstracted and the duration of tamoxifen use was calculated. Three hundred and thirty-one women had used tamoxifen (22 %); of these 84 (25 %) had completed four or more years of tamoxifen, the remainder stopped prematurely or were current users. For women with up to 1 year of tamoxifen use, the odds ratio for contralateral breast cancer was 0.37 (95 % CI 0.20–0.69; p = 0.001) compared to women with no tamoxifen use. Among women with 1–4 years of tamoxifen use the odds ratio was 0.53 (95 % CI 0.32–0.87; p = 0.01). Among women with four or more years of tamoxifen use the odds ratio was 0.83 (95 % CI 0.44–1.55; p = 0.55). Short-term use of tamoxifen for chemoprevention in BRCA1 and BRCA2 mutation carriers may be as effective as a conventional 5-year course of treatment.
Persistent Identifierhttp://hdl.handle.net/10722/206836

 

DC FieldValueLanguage
dc.contributor.authorGronwald, Jen_US
dc.contributor.authorRobidoux, Aen_US
dc.contributor.authorKim-Sing, Cen_US
dc.contributor.authorTung, Nen_US
dc.contributor.authorLynch, HTen_US
dc.contributor.authorFoulkes, WDen_US
dc.contributor.authorManoukian, Sen_US
dc.contributor.authorAinsworth, Pen_US
dc.contributor.authorNeuhausen, SLen_US
dc.contributor.authorDemsky, Ren_US
dc.contributor.authorEisen, Aen_US
dc.contributor.authorSinger, CFen_US
dc.contributor.authorSaal, Hen_US
dc.contributor.authorSenter, Len_US
dc.contributor.authorEng, Cen_US
dc.contributor.authorWeitzel, Jen_US
dc.contributor.authorMoller, Pen_US
dc.contributor.authorKwong, Aen_US
dc.date.accessioned2014-12-02T10:06:26Z-
dc.date.available2014-12-02T10:06:26Z-
dc.date.issued2014en_US
dc.identifier.citationBreast Cancer Research and Treatment, 2014, v. 146 n. 2, p. 421-7en_US
dc.identifier.urihttp://hdl.handle.net/10722/206836-
dc.description.abstractWomen with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80 %. Tamoxifen treatment of the first cancer has been associated with a reduction in the risk of a subsequent contralateral cancer. We studied 1,504 women with a known BRCA1 or BRCA2 mutation, 411 women with bilateral breast cancer (cases) and 1,093 women with unilateral breast cancer (controls) in a matched case–control study. Control women were of similar age and had a similar age of diagnosis of first breast cancer as the cases. For each woman who used tamoxifen, the starting and stopping dates were abstracted and the duration of tamoxifen use was calculated. Three hundred and thirty-one women had used tamoxifen (22 %); of these 84 (25 %) had completed four or more years of tamoxifen, the remainder stopped prematurely or were current users. For women with up to 1 year of tamoxifen use, the odds ratio for contralateral breast cancer was 0.37 (95 % CI 0.20–0.69; p = 0.001) compared to women with no tamoxifen use. Among women with 1–4 years of tamoxifen use the odds ratio was 0.53 (95 % CI 0.32–0.87; p = 0.01). Among women with four or more years of tamoxifen use the odds ratio was 0.83 (95 % CI 0.44–1.55; p = 0.55). Short-term use of tamoxifen for chemoprevention in BRCA1 and BRCA2 mutation carriers may be as effective as a conventional 5-year course of treatment.en_US
dc.languageengen_US
dc.publisherSpringer US. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0167-6806en_US
dc.relation.ispartofBreast Cancer Research and Treatmenten_US
dc.titleDuration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriersen_US
dc.typeArticleen_US
dc.identifier.emailKwong, A: avakwong@hkucc.hku.hken_US
dc.identifier.authorityKwong, A=rp01734en_US
dc.identifier.doi10.1007/s10549-014-3026-3en_US
dc.identifier.hkuros241602en_US
dc.identifier.volume146en_US
dc.identifier.issue2en_US
dc.identifier.spage421en_US
dc.identifier.epage7en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats